The collaboration will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
DrugDev and Exostar will combine their unique global identifiers for clinical operations personnel and facilities to address identity credential duplication and missing or incorrect records in systems.
Exostar offers SAM, a turnkey, cloud-based identity and access management solution that delivers single sign-on application access with multi-factor authentication. DrugDev provides its universal identifier called the DrugDev Golden Number for tracking persons and facilities across multiple data sources. The linkage will allow joint customers to securely combine data from all site-facing applications using single sign-on with non-site facing data sources.
Read the full release.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.